In vitro, and in various in vivo tumor xenograft models, rhApo2L/TRAIL exhibits single-agent antitumor activity and/or cooperation with certain conventional and targeted therapies.

• 在体外，以及多种种植瘤模型中， rhApo2L/TRAIL都显示出单药和/或协同的抗肿瘤疗效。